- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 10,742
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastric Cancer
- Interventions
- Docetaxel, Floxuridine, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- ER-Positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- Fulvestrant Run-In
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Interventions
- Conventional Surgery, Questionnaire Administration, Stereotactic Radiosurgery, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
- Procedure · Other · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Bethesda, Maryland + 1 more
- Conditions
- Prostate Cancer
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma
- Interventions
- medical chart review, questionnaire administration, management of therapy complications
- Other · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Not listed
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 15
- States / cities
- Palo Alto, California • New Haven, Connecticut • Chicago, Illinois + 11 more
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- Olaparib
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 4 more
- Conditions
- Brain Metastases, Cancer (With CNS Involvement)
- Interventions
- Staged Stereotactic Radiosurgery (SSRS), Fractionated Stereotactic Radiotherapy (FSRT)
- Radiation
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
- Interventions
- MBQ-167
- Drug
- Lead sponsor
- MBQ Pharma
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Sarasota, Florida • Nashville, Tennessee
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Galunisertib, Durvalumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • New York, New York • Nashville, Tennessee
- Conditions
- Gastro-Oesophageal Cancer
- Interventions
- Regorafenib, Placebo
- Drug · Other
- Lead sponsor
- Australasian Gastro-Intestinal Trials Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
- Interventions
- CB-103
- Drug
- Lead sponsor
- Cellestia Biotech AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
- Interventions
- Yttrium 90 glass microspheres
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Rochester, Minnesota + 2 more
- Conditions
- Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
- Procedure · Dietary Supplement · Biological + 1 more
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Advanced Cancer, Metastatic Cervical Cancer
- Interventions
- Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
- Interventions
- MX006
- Drug
- Lead sponsor
- Myricx Pharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Houston, Texas • San Antonio, Texas + 1 more
- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, denileukin diftitox
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma, Malignant Melanoma
- Interventions
- CT-011
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 9 more
- Conditions
- Thyroid Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Saad A Khan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- Postoperative chemotherapy, Perioperative chemotherapy
- Procedure
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 283
- States / cities
- Antioch, California • Duarte, California • Fremont, California + 210 more
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
- Interventions
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
- Conditions
- Colorectal Cancer
- Interventions
- oxaliplatin
- Drug
- Lead sponsor
- Prologue Research International
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Boca Raton, Florida • Louisville, Kentucky + 7 more
- Conditions
- Advanced Breast Cancer
- Interventions
- Bosutinib, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 11
- States / cities
- Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
- Conditions
- Melanoma
- Interventions
- pembrolizumab + epacadostat, pembrolizumab + placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 706 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 31 more